Advertisement
Canada Markets closed

  • S&P/TSX

    22,814.81
    +206.78 (+0.91%)
     

  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     

  • DOW

    40,589.34
    +654.27 (+1.64%)
     

  • CAD/USD

    0.7230
    -0.0005 (-0.0687%)
     

  • CRUDE OIL

    76.44
    -1.84 (-2.35%)
     

  • BTC-CAD

    93,895.06
    +2,346.16 (+2.56%)
     

  • CMC Crypto 200

    1,373.41
    +42.80 (+3.22%)
     

  • GOLD FUTURES

    2,385.70
    +32.20 (+1.37%)
     

  • RUSSELL 2000

    2,260.07
    +37.09 (+1.67%)
     

  • 10-Yr Bond

    4.2000
    -0.0560 (-1.32%)
     

  • NASDAQ

    17,357.88
    +176.16 (+1.03%)
     

  • VOLATILITY

    16.39
    -2.07 (-11.21%)
     

  • FTSE

    8,285.71
    +99.36 (+1.21%)
     

  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     

  • CAD/EUR

    0.6654
    -0.0013 (-0.19%)
     

Why Biohaven Stock Caught Fire This Week

George Budwell, The Motley Fool
·2 min read
Why Biohaven Stock Caught Fire This Week

Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.

Continue reading